【ChiCTR2600132897】Effectiveness of a Structured Diet and Exercise Plan on Sticking With It and Managing Cardiometabolic Health During and After Pregnancy
ChiCTR2600132897
结束
/
/
/
2026-09-20
/
/
Overweight and Obesity
Effectiveness of a Structured Diet and Exercise Plan on Sticking With It and Managing Cardiometabolic Health During and After Pregnancy
Effectiveness of a Structured Diet and Exercise Plan on Sticking With It and Managing Cardiometabolic Health During and After Pregnancy
i. To assess the status of dietary intake, physical activity, and related weight, blood pressure, heart rate, glucose tolerance, circulating free fatty acids, and total, LDL and HDL cholesterol changes occurring during pregnancy among women with a sedentary lifestyle and/or overweight/obesity. ii. To investigate whether the provision of a structured physical activity prescription improves compliance with physical activity recommendations among women with a sedentary lifestyle and/or overweight/obesity. iii. To investigate whether the provision of a structured diet prescription improves compliance with dietary recommendations among women with a sedentary lifestyle and/or overweight/obesity. iv. To determine the effectiveness of a structured physical activity prescription in controlling weight, blood pressure, heart rate, Hb concentration, glucose tolerance, circulating free fatty acids, total, LDL and HDL cholesterol during pregnancy and their subsequent return to prepregnancy levels among women with a sedentary lifestyle and/or overweight/obesity. v. To determine the effectiveness of a structured diet prescription in controlling weight, blood pressure, heart rate, Hb concentration, glucose tolerance, circulating free fatty acids, total, LDL and HDL cholesterol during pregnancy and their subsequent return to pre-pregnancy levels among women with a sedentary lifestyle and/or overweight/obesity. vi. To assess the effects of structured diet and exercise prescriptions on pregnancy outcomes among women with a sedentary lifestyle and/or overweight/obesity.
非随机对照试验
其它
No randomization. It will be squencial sampling. All eligible at Makole health center will be assigned to experiment group while all eligible at Makole Dispensary will be asigned to comparison group.
None
UDOM sponsorship for staff undertaking PhD studies
/
107
/
2025-04-01
2026-04-30
/
The study will include singleton pregnant women aged 18–35 with a sedentary lifestyle and/or overweight or obese. The study will recruit only pregnant women at 6–16 weeks of gestation. The study will only include women able to give valid informed consent and willing to participate and follow the prescription. The study will include singleton pregnant women aged 18–35 with a sedentary lifestyle and/oroverweight or obese. The study will recruit only pregnant women at 6–16 weeks of gestation. The study will only include women able to give valid informed consent and willing to participateand follow the prescription.;
请登录查看Gestation below six weeks will not be included due to the difficulty of diagnosing pregnancy. Also, if gestational age was not ascertained by ultrasound examination by the end of 13 weeks of their gestation will be excluded. Potential participants with multiple pregnancies will not be included to rule out the probable multiplicity of pregnancy changes. Under–18 women will not be included to exclude the possible effects of premature reproductive systems, while those above 35 will not be included to exclude the possible effects of pregnancy at an advanced age. Women already diagnosed with cardiovascular disease or for whom exercise is contraindicated will be excluded. All potential participants will be screened for contraindications using Canadian guidelines before enrolment. To minimise the loss of follow-ups, potential participants planning to relocate out of Dodoma City during the study period will be excluded.;
请登录查看University of Dodoma
/
University of Dodoma的其他临床试验
University of Dodoma的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示:#脐带间充质干细胞(#hUC-MSCs)
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点,索弗度肽(survodutide)成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构:国家卫生健康委办公厅、 2026-11-10
-
颁布机构:国家卫健委(原国家卫计委) 2026-11-10
-
颁布机构:国家药品审评中心(CDE) 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-04

